VANCOUVER, June 5, 2019 /PRNewswire/ - StillCanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) ("STIL" or the "Company") is pleased to announce it has entered a strategic relationship with Sarah Yetman, an expert in the international transportation of industrial hemp and CBD.
Ms. Yetman has overseen the shipment of tens of thousands of kilograms of CBD into the USA and other countries. Ms. Yetman is also active in the supply of CBD products and biomass globally and will be representing StillCanna products to her existing customer base.
Ms. Yetman will be responsible for:
- Arranging the shipment of biomass and CBD isolate and CBD distillate internationally;
- Arranging all applicable insurance policies and required certificates of origin;
- Organizing the clearance of shipments with the applicable Drug Enforcement Administration officials and customs officials;
- Organizing the delivery of the CBD product to end customers once the CBD product has cleared customs; and
- Organizing the product handling and testing at its final destination.
Ms. Yetman has been able to import products into the USA based sovereign ports of call and clear those products through customs using her existing relationships with both the Drug Enforcement Administration officials and US Customs officials.
"We are very impressed with the infrastructure that Sarah has been able to establish in both the USA and abroad," stated Jason Dussault, CEO of StillCanna. "Her expertise and experience provides an invaluable service to StillCanna and is an important link in our supply chain. This relationship allows our products to reach a wider international audience. Ms. Yetman also brings a broad international base of buyers for both CBD products and hemp biomass."
"I couldn't be more pleased to be working with StillCanna and providing them with the global logistics they require," said Sarah Yetman. "The contacts and infrastructure I have established is a custom fit for both the Company and myself. I look forward to implementing and overseeing the first of many shipments."
About StillCanna Inc.
StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company's market share in the European CBD industry.
On Behalf of the Board,
Chief Financial Officer and Director
Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the Company's intention to ship its first CBD products from Poland to the USA within the next few weeks and that the acquisition of Olimax is expected to result in an increase in the Company's market share of the European CBD industry. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that Company will be able to ship its first CBD products from Poland to the USA within the next few weeks and that the acquisition of Olimax will result in an increase in the Company's market share of the European CBD industry. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that that Company will not be able to ship its first CBD products from Poland to the USA within the next few weeks, or at all and that the acquisition of Olimax will not result in an increase in the Company's market share of the European CBD industry. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
SOURCE StillCanna Inc.